AU2020319005B2 - Inhibitors of cyclin-dependent kinase 7 and uses thereof - Google Patents

Inhibitors of cyclin-dependent kinase 7 and uses thereof

Info

Publication number
AU2020319005B2
AU2020319005B2 AU2020319005A AU2020319005A AU2020319005B2 AU 2020319005 B2 AU2020319005 B2 AU 2020319005B2 AU 2020319005 A AU2020319005 A AU 2020319005A AU 2020319005 A AU2020319005 A AU 2020319005A AU 2020319005 B2 AU2020319005 B2 AU 2020319005B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
certain embodiments
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020319005A
Other languages
English (en)
Other versions
AU2020319005A1 (en
Inventor
Nathanael S. Gray
Zhixiang HE
Nicholas Paul Kwiatkowski
Yanke LIANG
Tinghu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2020319005A1 publication Critical patent/AU2020319005A1/en
Application granted granted Critical
Publication of AU2020319005B2 publication Critical patent/AU2020319005B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020319005A 2019-07-23 2020-07-22 Inhibitors of cyclin-dependent kinase 7 and uses thereof Active AU2020319005B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877788P 2019-07-23 2019-07-23
US62/877,788 2019-07-23
PCT/US2020/043132 WO2021016388A1 (en) 2019-07-23 2020-07-22 Inhibitors of cyclin-dependent kinase 7 and uses thereof

Publications (2)

Publication Number Publication Date
AU2020319005A1 AU2020319005A1 (en) 2021-12-23
AU2020319005B2 true AU2020319005B2 (en) 2026-01-08

Family

ID=74192704

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020319005A Active AU2020319005B2 (en) 2019-07-23 2020-07-22 Inhibitors of cyclin-dependent kinase 7 and uses thereof

Country Status (7)

Country Link
US (1) US20230242534A9 (https=)
EP (1) EP4003335A4 (https=)
JP (1) JP7680999B2 (https=)
CN (1) CN114401719A (https=)
AU (1) AU2020319005B2 (https=)
CA (1) CA3147106A1 (https=)
WO (1) WO2021016388A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
JP7660063B2 (ja) 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
US20230114207A1 (en) * 2019-12-24 2023-04-13 Dana-Farber Cancer Institute, Inc. The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US20190055248A1 (en) * 2014-12-23 2019-02-21 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclindependent kinase 7 (cdk7)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
ES2661883T3 (es) * 2012-07-09 2018-04-04 Novartis Ag Biomarcadores asociados con inhibidores de CDK
HK1246645A1 (zh) * 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190055248A1 (en) * 2014-12-23 2019-02-21 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclindependent kinase 7 (cdk7)
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Also Published As

Publication number Publication date
JP7680999B2 (ja) 2025-05-21
EP4003335A4 (en) 2024-01-10
AU2020319005A1 (en) 2021-12-23
JP2022541644A (ja) 2022-09-26
US20230242534A9 (en) 2023-08-03
WO2021016388A1 (en) 2021-01-28
CA3147106A1 (en) 2021-01-28
EP4003335A1 (en) 2022-06-01
CN114401719A (zh) 2022-04-26
US20220281874A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
US12168663B2 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3273966B1 (en) Inhibitors of cyclin-dependent kinases
AU2020319005B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
AU2019413694B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
US10342798B2 (en) Fused bicyclic pyrimidine derivatives and uses thereof
AU2020357983B2 (en) Tricyclic kinase inhibitors and uses thereof
WO2016210296A1 (en) 4,6-pyrimidinylene derivatives and uses thereof
CA2988330C (en) 4,6-pyrimidinylene derivatives and uses thereof